Radotinib for CML patients after prior TKI failure
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests radotinib (a targeted pill) in people with chronic-phase Philadelphia chromosome–positive CML whose previous TKIs stopped working or could not be tolerated. It aims to improve control of the leukemia while checking safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have chronic-phase Ph+ CML and your prior TKI treatment failed or you could not tolerate it (including imatinib).
- Your performance status is ECOG 0, 1, or 2 (you can do some daily activities).
- Your blood counts and body organ tests fit the study limits, including enough platelets and acceptable liver and kidney tests.
- You do not have blast crisis or accelerated-phase CML at screening, and you do not have a specific mutation called T315I.
- You can follow pregnancy prevention rules if you could become pregnant, and you can provide consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for people with chronic myeloid leukemia (CML) whose disease is resistant to or intolerant of current standard drugs. The goal is to see if the study drug works better when combined with another drug, and to check its safety.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This trial tests if people with chronic myeloid leukemia (CML) who have already tried to stop their TKI medication once and lost a deep remission, can safely stop their TKI again after taking a newer drug called asciminib. The goal is to stay in remission (no detectable leukemia) without needing daily medication.
This trial studies ponatinib as a second treatment for chronic myeloid leukemia (CML) when it didn’t fully respond or couldn’t be tolerated with at least one prior CML pill. It aims to see whether ponatinib can better control leukemia levels after earlier treatments.
This trial tests if a short course of pioglitazone (a diabetes drug) before stopping your TKI therapy can help you stay in remission longer. It is for people with chronic myeloid leukemia (CML) who have already lost their remission after a first or later attempt to stop TKI treatment.
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
Hear when a new Chronic Myeloid Leukemia, Chronic Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.